triazoles has been researched along with doravirine in 91 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 35 (38.46) | 24.3611 |
2020's | 56 (61.54) | 2.80 |
Authors | Studies |
---|---|
Asante-Appiah, E; Burch, J; Campeau, LC; Cauchon, E; Côté, B; DiStefano, D; Ducharme, Y; Falgueyret, JP; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Li, Y; Lu, M; Miller, MD; Sachs, N; Tawa, P; Witmer, M; Yan, Y | 1 |
Asante-Appiah, E; Bayly, C; Bédard, L; Blouin, M; Burch, JD; Campeau, LC; Cauchon, E; Chan, M; Chefson, A; Côté, B; Coulombe, N; Cromlish, W; Debnath, S; Deschênes, D; Ducharme, Y; Dupont-Gaudet, K; Falgueyret, JP; Forget, R; Gagné, S; Gauvreau, D; Girardin, M; Guiral, S; Langlois, E; Li, CS; Nguyen, N; Ouellet, S; Papp, R; Plamondon, S; Roy, A; Roy, S; Seliniotakis, R; St-Onge, M; Tawa, P; Truchon, JF; Vacca, J; Wrona, M; Yan, Y | 1 |
Feng, M; Grobler, JA; Hazuda, DJ; Lai, MT; Miller, MD; Wang, D | 1 |
Ancona, JK; Anderson, MS; Butterton, JR; Cilissen, C; De Lepeleire, I; Dockendorf, MF; Gilmartin, J; Guo, Y; Liu, R; Tetteh, E; Van Bortel, L; Wagner, JA | 1 |
Cao, Y; Gauthier, DR; Humphrey, G; Itoh, T; Journet, M; Mangion, I; Sherry, BD; Tschaen, DM | 1 |
Anderson, MS; Butterton, JR; De Lepeleire, I; Gilmartin, J; Guo, Y; Liu, R; Robberechts, M; Schürmann, D; Sobotha, C; Wagner, F; Wagner, JA; Yee, KL | 1 |
Blair, W; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Miller, MD; Sachs, NA; Xu, M | 1 |
Akram, A; Ambrose, Z; Hughes, SH; Melody, K; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
Cao, Y; Gauthier, DR; Helmy, R; Sheng, H; Yang, R; Zhang, LK; Zheng, J | 1 |
Anderson, MS; Butterton, JR; Fan, L; Hussaini, A; Khalilieh, S; Liu, R; Rizk, ML; Ross, LL; Shah, V; Song, I; Yee, KL | 1 |
Auger, P; Di Spirito, M; Fan, L; Iwamoto, M; Khalilieh, SG; Lai, MT; Liu, R; Sanchez, RI; Triantafyllou, I; Yee, KL | 1 |
Fan, L; Iwamoto, M; Jordan, H; Khalilieh, S; Maklad, N; Martell, M; Sanchez, RI; Triantafyllou, I; Yee, KL | 1 |
Auger, P; Fan, L; Iwamoto, M; Khalilieh, S; Lasseter, KC; Liu, R; Marbury, T; Sanchez, RI; Stypinski, D; Triantafyllou, I; Yee, KL | 1 |
Behm, MO; Fackler, P; Fan, L; Yee, KL | 1 |
Behm, MO; Fackler, P; Levine, V; Liu, R; Panebianco, D; Yee, KL | 1 |
Anderson, MS; Brejda, J; Butterton, JR; Judge, T; Khalilieh, SG; Liu, R; Manthos, H; Sanchez, RI; Yee, KL | 1 |
Dunzo, E; Fan, L; Heber, W; Hussaini, A; Iwamoto, M; Khalilieh, SG; Liu, R; Triantafyllou, I; Yee, KL | 1 |
Anderson, MS; Behm, MO; Butterton, JR; Fan, L; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Li, Y; Liang, Y; Liu, R; Lu, B; Sanchez, RI; Tatavarti, A; Yee, KL | 1 |
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X | 1 |
Colombier, MA; Molina, JM | 1 |
Eissa, NA; Wilby, KJ | 1 |
Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
Deeks, ED | 1 |
Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Di Carlo, D; Gennari, W; Marcelin, AG; Paraskevis, D; Perno, CF; Santoro, MM; Soulie, C; Sterrantino, G; Storto, A; Zazzi, M | 1 |
Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J | 1 |
Claussen, A; de Greef, R; Ouerdani, A; Wenning, L; Yee, KL | 1 |
Bleasby, K; Chan, GH; Fillgrove, KL; Houle, R; Lin, M; Lu, B; Newton, DJ; Palamanda, J; Sanchez, RI | 1 |
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
Ankrom, W; Fan, L; Iwamoto, M; Khalilieh, S; Mitra, P; Sanchez, RI; Sterling, LM; Stoch, SA; Triantafyllou, I; Wolford, D; Yee, KL | 1 |
Anderson, MS; Fan, L; Iwamoto, M; Khalilieh, SG; Laethem, T; Rasmussen, S; Sanchez, RI; Sura, M; van Bortel, L; van Lancker, G; Yee, KL | 1 |
Deschamps, K; Fan, L; Iwamoto, M; Jordan, HR; Khalilieh, SG; Martell, M; Sanchez, RI; Vaynshteyn, K; Yee, KL | 1 |
Cislak, D; Fan, L; Iwamoto, M; Jordan, HR; Khalilieh, S; Martell, M; Sanchez, RI; Yee, KL | 1 |
Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y | 1 |
Bouhajib, M; Fan, L; Iwamoto, M; Khalilieh, S; Sanchez, RI; Searle, S; Vaynshteyn, K; Yee, KL | 1 |
Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X | 1 |
DeJesus, E; Hanna, G; Hwang, C; Kumar, S; Lombaard, J; Martin, E; Molina, JM; Orkin, C; Rodgers, A | 1 |
Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X | 1 |
Boyle, A; Khoo, S; Marzolini, C; Moss, CE | 1 |
Blevins, SR; Chastain, DB; Cluck, DB; Hester, EK | 1 |
Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
Hazuda, D; Hwang, C; Lai, MT | 1 |
Grobler, JA; Markowitz, M | 1 |
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K | 1 |
Dormer, PG; Forrest, WP; Helmy, R; Reibarkh, M; Rudd, ND; Walsh, PL; Williamson, RT; Wuelfing, WP | 1 |
Abdi, B; Andreoni, M; Antinori, A; Armenia, D; Bertoli, A; Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Forbici, F; Gennari, W; Jary, A; Marcelin, AG; Mussini, C; Perno, CF; Santoro, MM; Soulie, C; Storto, A | 1 |
Aguilera, A; Alejos, B; Álvarez, M; Blanco, JR; Caballero, E; Espinosa, N; García, F; García-Álvarez, M; García-Bujalance, S; García-Fraile, LJ; Gómez-Sirvent, JL; Guerrero-Beltrán, C; Iborra, A; Imaz, A; Iribarren, JA; Martínez, M; Martínez-Sanz, J; Masiá, M; Montero, M; Moreno, S; Olalla, J; Peraire, J; Portilla, J; Rivero, M; Rodríguez, C; Vidal-Ampurdanes, MC | 1 |
DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
Boffito, M; Connolly, S; Fedele, S; McClure, M; Milinkovic, A; Moyle, G; Pereira, B; Thomas, L; Wang, X; Yener, D | 1 |
Alves Saldanha, S; André, P; Buclin, T; Cavassini, M; Choong, E; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Günthard, HF; Marzolini, C | 1 |
Talwani, R; Temesgen, Z | 1 |
Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R | 1 |
Azeem, SM; Frey, KM; Muwonge, AN; Tabassum, T | 1 |
Dockendorf, MF; Fackler, PH; Fan, L; Iwamoto, M; Khalilieh, SG; Mittal, S; Stoch, SA; Triantafyllou, I; Yee, KL | 1 |
Fulco, PP; Herity, LB | 1 |
Hewlett, K; Hughes, SH; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
Iwamoto, M; Khalilieh, S; Sanchez, R; Stoch, SA; Wenning, L; Yee, KL | 1 |
Kandala, B; Vaddady, P; Yee, KL | 1 |
Arribas, JR; Battegay, M; Béguelin, C; Bhagani, S; Cinque, P; Collins, S; Cotter, A; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, P; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Winston, A | 1 |
Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P | 1 |
Boccuto, A; Dragoni, F; Giammarino, F; Giannini, A; Hosseini, BA; Saladini, F; Shafer, RW; Vicenti, I; Zazzi, M | 1 |
Cabalu, TD; Dreyer, D; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Kuo, Y; Liu, Y; McClain, S; Sanchez, RI; Stoch, SA; Triantafyllou, I; Wenning, L; Yee, KL | 1 |
Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ | 1 |
Abdel-Daim, MM; Afify, MA; Ahmed, IGG; Alkahtani, TA; Alrowili, ASM; Altulayhi, RI; Bin-Jumah, M; Ghozy, S | 1 |
Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K | 1 |
Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
Alegete, P; Kancherla, P; Kokkirala, TK; Suryakala, D | 1 |
Brenner, BG; Ibanescu, RI; Oliveira, M; Routy, JP; Thomas, R | 1 |
Hans, L; Moorhouse, M; Steegen, K; Venter, WD; Wensing, AM | 1 |
Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; DeJesus, E; Eves, K; Grandhi, A; Hanna, GJ; Hwang, C; Molina, JM; Olsen Klopfer, S; Robertson, MN; Sklar, P; Yazdanpanah, Y | 1 |
Godela, R; Gummadi, S | 1 |
Bouchet-Crivat, F; Lê, MP; Mandelbrot, L; Pencolé, L; Peytavin, G | 1 |
Ciccullo, A; D'Angelillo, A; Di Giambenedetto, S; Farinacci, D; Iannone, V; Lombardi, F; Tamburrini, E; Visconti, E | 1 |
Challenger, E; Else, L; Imaz, A; Khoo, S; Niubó, J; Penchala, SD; Podzamczer, D; Prieto, P; Rigo-Bonin, R; Saumoy, M; Scévola, S; Silva-Klug, A; Soriano, I; Tiraboschi, J | 1 |
Asante-Appiah, E; Grobler, JA; Hazuda, D; Lai, J; Martin, EA; Petropoulos, CJ; Sklar, P; Walworth, C; Wan, H; Yang, D | 1 |
Aherfi, S; Banti, E; Dhiver, C; Motte, A; Solas, C | 1 |
Khoo, S; Stockdale, AJ | 1 |
Antinori, S; Baldelli, S; Bisinella, GC; Cattaneo, D; Cossu, MV; Fusi, M; Gervasoni, C; Meraviglia, P; Micheli, V; Resnati, C; Vimercati, S | 1 |
Cattelan, AM; Leoni, D; Mazzitelli, M; Putaggio, C; Sasset, L | 1 |
Cai, W; Chen, M; Lan, G; Lan, Y; Liang, S; Ma, Y; Ni, M; Sun, Z; Wang, J; Yan, L; Yu, F; Zhang, F; Zhang, H; Zhang, X | 1 |
Bailón, L; Curran, A; Else, L; Graterol, F; Imaz, A; Khoo, S; Moltó, J; Paredes, R; Pérez, F; Ramos, N; Sandoval, D | 1 |
Ciccullo, A; D'Angelillo, A; Farinacci, D; Giambenedetto, SD; Iannone, V; Lamanna, F; Lombardi, F; Moschese, D; Passerotto, RA | 1 |
Bociąga-Jasik, M; Hlebowicz, M; Jakubowski, P; Parczewski, M; Raczyńska, A; Scheibe, K; Szetela, B; Szymczak, A; Urbańska, A; Łojewski, W | 1 |
Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
Bukkems, VE; Burger, DM; Colbers, A; Freriksen, JJM; Greupink, R; Roelofsen, D; Svensson, EM; van Drongelen, J; van Ewijk-Beneken Kolmer, EWJ; van Hove, H | 1 |
Baker, CR; Fulco, PP; Porter, AM | 1 |
Arnold, E; Bijnens, M; Das, K; De Wijngaert, B; Herdewijn, P; Martinez, SE; Nguyen, H; Pannecouque, C; Schols, D; Singh, AK; Uyttersprot, K | 1 |
Antoni, MD; Castelli, F; Cattelan, AM; Fabbiani, M; Ferraresi, A; Lapadula, G; Mazzitelli, M; Putaggio, C; Quiros-Roldan, E; Ripamonti, D; Zuglian, G | 1 |
Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
Cottrell, ML; Imaz, A; Kashuba, AD; Podzamczer, D; Schauer, AP; Sykes, C | 1 |
13 review(s) available for triazoles and doravirine
Article | Year |
---|---|
Doravirine: a review.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles | 2018 |
Clinical Pharmacokinetics and Drug Interactions of Doravirine.
Topics: Drug Interactions; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
Doravirine: A Return of the NNRTI Class?
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles | 2020 |
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viral Load | 2020 |
Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Topics: Anti-HIV Agents; Cytochrome P-450 CYP3A; HIV Infections; HIV-1; Humans; Japan; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Drug Interactions; Female; Food-Drug Interactions; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2020 |
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles | 2020 |
Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Triazoles | 2021 |
Doravirine: its role in HIV treatment.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
30 trial(s) available for triazoles and doravirine
Article | Year |
---|---|
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Topics: Adult; Area Under Curve; Chromatography, Liquid; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Administration Schedule; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Triazoles | 2015 |
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
Topics: Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Male; Middle Aged; Placebos; Plasma; Pyridones; RNA, Viral; Treatment Outcome; Triazoles; Young Adult | 2016 |
A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Topics: Adult; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Fasting; Female; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2017 |
Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; Headache; Healthy Volunteers; Humans; Male; Middle Aged; Pyridones; Triazoles | 2017 |
Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Topics: Adult; Area Under Curve; Atorvastatin; Drug Interactions; Female; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2017 |
Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
Topics: Adult; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2017 |
Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Area Under Curve; Biological Availability; Drug Administration Schedule; Fasting; Female; Healthy Volunteers; Humans; Male; Middle Aged; Patient Safety; Pyridones; Reverse Transcriptase Inhibitors; Sex Factors; Triazoles | 2017 |
The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles | 2017 |
A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2017 |
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Topics: Absorption, Physiological; Administration, Intravenous; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Humans; Male; Metabolome; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tissue Distribution; Triazoles; Young Adult | 2019 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.
Topics: Adult; Aluminum Hydroxide; Antacids; Drug Interactions; Female; Humans; Magnesium Hydroxide; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Simethicone; Triazoles | 2019 |
Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.
Topics: Adult; Area Under Curve; Drug Interactions; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2020 |
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult | 2019 |
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Topics: Adult; Analgesics, Opioid; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Outcome Assessment, Health Care; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles | 2020 |
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Treatment Outcome; Triazoles | 2020 |
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2019 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2020 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prospective Studies; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Tuberculosis; Young Adult | 2020 |
Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Dried Blood Spot Testing; Female; Half-Life; Humans; Injections, Intramuscular; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2020 |
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Topics: Adult; Alkynes; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Pyridones; Reverse Transcriptase Inhibitors; Rifabutin; Rifampin; Triazoles; Young Adult | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Triazoles; Young Adult | 2021 |
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease.
Topics: Chromatography, Liquid; Dialysis Solutions; HIV Infections; Humans; Kidney Failure, Chronic; Male; Pyridones; Renal Dialysis; Tandem Mass Spectrometry; Triazoles | 2022 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
48 other study(ies) available for triazoles and doravirine
Article | Year |
---|---|
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Macrophages; Monocytes; Pyridones; Triazoles; Virus Replication | 2014 |
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; Crystallography, X-Ray; Dogs; Drug Discovery; Drug Resistance, Viral; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Pyridones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Triazoles | 2014 |
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Selection, Genetic; Triazoles | 2015 |
Highly efficient synthesis of HIV NNRTI doravirine.
Topics: Aldehydes; HIV Infections; HIV Reverse Transcriptase; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2015 |
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Viral; Gene Expression; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Pyridones; Rilpivirine; Triazoles | 2016 |
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Topics: Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles; Virus Replication | 2016 |
Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Contamination; HIV Infections; Humans; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2016 |
The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Half-Life; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Young Adult | 2017 |
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; France; Gene Frequency; Greece; HIV Infections; HIV-1; Humans; Italy; Mutation, Missense; Prevalence; Pyridones; Triazoles | 2019 |
Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2019 |
Topics: Animals; Biological Transport; Cell Line; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; HEK293 Cells; Hepatocytes; Humans; Kinetics; Madin Darby Canine Kidney Cells; Membrane Transport Proteins; Pyridones; Triazoles | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Topics: Adult; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Fluorenes; Humans; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Pyridones; Quinoxalines; Sulfonamides; Triazoles | 2019 |
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2019 |
Rational Design of Doravirine: From Bench to Patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Design; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Translational Research, Biomedical; Triazoles | 2020 |
Probing in Vitro Release Kinetics of Long-Acting Injectable Nanosuspensions via Flow-NMR Spectroscopy.
Topics: Chemistry, Pharmaceutical; Drug Compounding; Drug Liberation; Drug Stability; Excipients; In Vitro Techniques; Injections; Magnetic Resonance Spectroscopy; Nanoparticles; Particle Size; Pyridones; Solubility; Suspensions; Triazoles | 2020 |
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Topics: Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
Topics: Algorithms; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; Humans; Mutation; Prevalence; Pyridones; Spain; Triazoles | 2020 |
Pharmacokinetics of once-daily doravirine over 72 h following drug cessation.
Topics: Pharmaceutical Preparations; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2020 |
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI
Topics: Amides; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Limit of Detection; Linear Models; Piperazines; Pyridones; Reference Standards; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2020 |
Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Topics: Allosteric Site; Anti-HIV Agents; Binding Sites; Drug Resistance, Viral; Enzyme Assays; Gene Expression; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics; Triazoles; Urea | 2020 |
Doravirine Use in Treatment-Experienced HIV-Positive Patients.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Pyridones; Pyrimidines; Rilpivirine; Triazoles | 2021 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Topics: Age Factors; Anti-Retroviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Triazoles | 2020 |
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Topics: Anti-HIV Agents; Clone Cells; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Changes in weight and BMI with first-line doravirine-based therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2021 |
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles | 2021 |
A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Lamivudine; Limit of Detection; Linear Models; Pyridones; Reproducibility of Results; Tablets; Tenofovir; Triazoles | 2021 |
Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
Topics: Anti-HIV Agents; Cell Culture Techniques; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Pyridones; Retrospective Studies; South Africa; Triazoles | 2021 |
A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets.
Topics: Chromatography, High Pressure Liquid; Lamivudine; Pyridones; Tablets; Tenofovir; Triazoles | 2021 |
Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model.
Topics: Cotyledon; HIV-1; Humans; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Pyridones; Triazoles | 2021 |
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF.
Topics: HIV Infections; HIV-1; Humans; Pyridones; Triazoles; Virus Replication | 2022 |
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
High penetration of doravirine in the central nervous system: What are the benefits?
Topics: Central Nervous System; Humans; Pyridones; Triazoles | 2022 |
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Tenofovir; Triazoles | 2021 |
Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Male; Middle Aged; Oxazines; Piperazines; Polypharmacy; Pyridones; Retrospective Studies; Treatment Outcome; Triazoles; Viral Load | 2021 |
Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
Evaluation of doravirine-based regimen population target in a large Italian clinical center.
Topics: Anti-HIV Agents; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Poland; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2021 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
Topics: Female; Humans; Maternal-Fetal Exchange; Models, Biological; Perfusion; Placenta; Pregnancy; Pyridones; Triazoles | 2022 |
Administration of Crushed Doravirine via Nasojejunal Feeding Tube in a Patient With Treatment-Experienced Human Immunodeficiency Virus.
Topics: HIV; Humans; Intubation, Gastrointestinal; Pyridones; Triazoles | 2023 |
Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Topics: Anti-HIV Agents; Cryoelectron Microscopy; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutation; Nitriles; Protein Conformation; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles | 2022 |
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study.
Topics: Anti-HIV Agents; DNA-Directed RNA Polymerases; Female; HIV Infections; Humans; Integrase Inhibitors; Male; Middle Aged; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Triazoles | 2022 |
Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma.
Topics: Amides; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Raltegravir Potassium; Reproducibility of Results; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Triazoles | 2022 |